Active	Status	Sponsor type	Region	Phase	Filter
7 Active 4 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Preusser, Matthias
LEGATO, NCT05904119: Lomustine with and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study	Recruiting	3	411	NA	Lomustine, Reirradiation	European Organisation for Research and Treatment of Cancer - EORTC, Swiss Group for Clinical Cancer Research	First Progression of Glioblastoma	09/27	02/28
TUXEDO-3, NCT05865990: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease	Active, not recruiting	2	63	Europe	Patritumab deruxtecan, HER3-DXd	MedSIR, Daiichi Sankyo	Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult	12/25	10/26
REPOSE, NCT06315010: REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis	Not yet recruiting	2	20	NA	Repotrectinib, BMS-986472, TPX-0005	MedSIR, Medical University of Vienna	NSCLC, Brain Metastases, ROS1 Gene Rearrangement	03/27	04/28
TUXEDO-4, NCT06048718: T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases	Recruiting	2	27	Europe	Trastuzumab-Deruxtecan (T-DXd), DS-8021a, ENHERTU	MedSIR, Daiichi Sankyo	Breast Cancer, Metastatic Breast Cancer	09/25	07/26
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access	Recruiting	N/A	4975	Europe, RoW	RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon	European Organisation for Research and Treatment of Cancer - EORTC	All Tumor Types	03/26	03/26
Fuereder, Thorsten
PACE ACE, NCT04278092 / 2019-003114-13: Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure	Recruiting	2	50	Europe	Paclitaxel, Taxol, Cetuximab, Erbitux	Medical University of Vienna, , Med. Univ. Wien	Head and Neck Squamous Cell Carcinoma	12/23	07/24
NCT02718820: Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer	Completed	1/2	22	Europe	Docetaxel, Taxotere, Pembrolizumab, Keytruda	Medical University of Vienna	Head and Neck Carcinoma	12/21	12/21
Kuehrer, Irene
No trials found